TrialThe Lancet. Infectious diseases2022

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.

David Ishola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.